APA (7th ed.) Citation

Mahadevan, D., Barve, M., Mahalingam, D., Parekh, J., Kurman, M., Strauss, J., . . . Zhou, D. (2025). First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies. Journal of Hematology & Oncology, 18(1), 1. https://doi.org/10.1186/s13045-025-01753-8

Chicago Style (17th ed.) Citation

Mahadevan, Daruka, et al. "First in Human Phase 1 Study of DT2216, a Selective BCL-xL Degrader, in Patients with Relapsed/refractory Solid Malignancies." Journal of Hematology & Oncology 18, no. 1 (2025): 1. https://doi.org/10.1186/s13045-025-01753-8.

MLA (9th ed.) Citation

Mahadevan, Daruka, et al. "First in Human Phase 1 Study of DT2216, a Selective BCL-xL Degrader, in Patients with Relapsed/refractory Solid Malignancies." Journal of Hematology & Oncology, vol. 18, no. 1, 2025, p. 1, https://doi.org/10.1186/s13045-025-01753-8.